News coverage about Penumbra (NYSE:PEN) has been trending somewhat positive recently, according to Accern. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Penumbra earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.0270061990657 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

Penumbra (NYSE PEN) traded up $1.10 during trading hours on Wednesday, reaching $93.60. The company’s stock had a trading volume of 155,608 shares, compared to its average volume of 300,352. The company has a market capitalization of $3,107.08, a price-to-earnings ratio of -425.45, a price-to-earnings-growth ratio of 98.09 and a beta of 0.19. Penumbra has a 12-month low of $74.15 and a 12-month high of $116.35.

Several brokerages recently commented on PEN. Canaccord Genuity increased their price target on Penumbra from $100.00 to $113.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. BMO Capital Markets increased their price target on Penumbra from $96.00 to $117.00 and gave the company an “outperform” rating in a research report on Wednesday, November 8th. JPMorgan Chase & Co. cut Penumbra from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Finally, Zacks Investment Research cut Penumbra from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $111.50.

In other Penumbra news, CEO Adam Elsesser sold 62,862 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $105.15, for a total value of $6,609,939.30. Following the sale, the chief executive officer now owns 1,191,887 shares in the company, valued at $125,326,918.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Arani Bose sold 8,133 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $103.50, for a total value of $841,765.50. Following the completion of the sale, the insider now owns 700,815 shares in the company, valued at approximately $72,534,352.50. The disclosure for this sale can be found here. Insiders sold 295,230 shares of company stock worth $29,788,550 in the last 90 days. Corporate insiders own 13.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://theolympiareport.com/2018/02/15/penumbra-pen-earns-media-sentiment-rating-of-0-23.html.

About Penumbra

Penumbra, Inc is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.

Insider Buying and Selling by Quarter for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.